Monographie - Bortezomib

Viimeisin päivitys :
03/05/2024

Bortezomib

Kemiallinen rakenne

Kauppanimi

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Bemoncaz	Meksiko
Bicavan	Chile
Biemib	Turkki
Bomib	Meksiko
Borater	Argentiina
Borcade	Turkki
Bormib	Argentiina
Bortezomib	New Zealand
Bortezun	Ecuador
Bortrac	Ecuador, Marokko
Bortzo	Marokko
Botemib	Chile, Ecuador, Marokko
Bozix	Chile, Marokko
Bozob	Argentiina, Ecuador, Marokko
Bromadene	Argentiina
Egybort	Intia
Elomaziv	Meksiko
Gysatri	Argentiina
Miasoma	Argentiina
Mibor	Marokko
Multizom	Argentiina
Rebtik	Chile
Velcade	Argentiina, Australia, Belgia, Chile, Egypti, Espanja, Hollanti, Irlanti, Islanti, Iso-Britannia, Italia, Itävalta, Japani, Kanada, Kolumbia, Kreikka, Luxemburg, Malesia, Meksiko, New Zealand, Norja, Portugali, Puola, Ranska, Romania, Ruotsi, Saksa, Saudi-Arabia, Suomi, Sveitsi, Tanska, Turkki, Unkari, Venezuela, Yhdistyneet arabiemiirikunnat, Yhdysvallat
Velcord	Marokko
Vortemyel	Romania
Zefra	Argentiina
Zegomib	Romania
Zuricade	Meksiko

Viitteet : Bortezomib

	Tyyppi	Julkaisu
1911	Laboratorio	Bortezomib (Velcade®) - Summary of Product Characteristics Janssen-Cilag Ltd 2016
2010	Lehti	André P, Cisternino S, Chiadmi F, Toledano A, Schlatter J, Fain O, Fontan JE. Stability of bortezomib 1 mg/ml solution in plastic syringe and glass vial. Ann Pharmacotherapy 2005 ; 39: 1462-1466.
2011	Lehti	Friess D, Nguyen HC, Lipp HP. HPLC-stabilitätuntersuchungen zu rekonstituierten Bortezomib-Lösungen. Krankenhauspharmazie 2005 ; 26, 6: 206-210.
2232	Lehti	Walker SE, Milliken D, Law S. Stability of Bortezomib Reconstituted with 0.9% Sodium Chloride at 4°C and Room Temperature (23°C) Can J Hosp Pharm 2008 ; 61, 1: 14-20.
3190	Lehti	Bolognese A, Esposito A, Manfra M, Catalano L, Petruzziello F, Martorelli MC, Pagliuca R, Mazzarelli V, Ottiero M, Scalfaro M, An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. Advance in Haematology 2009 Article ID 704928, 5 page
3240	Ilmoitus	Perissutti M, Vigneron J, Zenier H, May I, Demoré B. Etude de la stabilité d'une solution de bortézomib à 1 mg/mL conditionnée en seringue de polypropylène. Congrès SFPO 2011
3337	Lehti	Carati D, Masini C, Minguzzi M, Petocchi B, Romanazzi C, Rondoni C, Sangiorgi E, Sferra S, Simonetta S, Stancari A, Locchi F, Z Stability of bortezomib reconstituted under clinical use conditions in original vials and polypropylene syringes at 4 °C and room temperature. EJHP 2012 ; 19: 428-431.
3349	Lehti	Bosch-Ojeda C, Sanchez-Rojas M.F, Espinosa-Bosch M. Chemical stability of bortezomib solutions in original manufacturer vials. Int J Pharm Bio Sci 2012 ; 2, 3: 344-350.
3418	Lehti	Berruezo garcia J, Espinosa Bosch M, Sanchez Rojas F, Bosch Ojeda C Chemical stability of bortezomib solutions in original manufacturer vial at room temperature and in syringe at 4°C. Int J Pharm Bio Sci 2013 ; 3, 1: 449-458.
3447	Ilmoitus	Giovanelli M, Vigneron J, May I, Nicolas A. Etude de la stabilité d’une solution de bortézomib à 2,5 mg/mL par chromatographie liquide à haute performance couplée à un détecteur à barrettes de diodes et à un détecteur évaporatif à diffusion de lumière. SFPO Congress, Mandelieu, France 2013
3537	Lehti	Lipp HP, Gfrörer W, Riedmüller S. Bortezomib zur subkutanen Applikation. Krankenhauspharmazie 2013 ; 34,11: 500-505.
3688	Lehti	Walker S.E, Charbonneau L.F, Law S. Stability of bortezomib 2.5 mg/mL in vials and syringes stored at 4°C and room temperature (23°C). Can J Hosp Pharm 2014 ; 67, 2: 102-107
4137	Lehti	Patel T, Sewell G. Short Report : Extended Stability Studies on Bortezomib Injection and Infusions of Cisplatin and Pemetrexed (all Accord Healthcare). Newsletter Stabilis 2018 41;2-6
4485	Lehti	Law S, Charbonneau L, Iazetta J, Perks W, Ma N, Walker S.E. Stability of Generic Formulations of Bortezomib 1.0 and 2.5 mg/mL in Vials and Syringes Stored 4°C and Room Temperature (23°C) Can J Hosp Pharm 2021 ;74;1:57-69

Mentions Légales